Hepatology

A multicentre study suggests selected Child-Pugh B liver cancer patients may benefit from first-line atezolizumab/bevacizumab despite poorer survival outcomes.

In 252 adults with autoimmune liver disease, health related quality of life remained stable over 35 months, with modest psychological improvement and poorer outcomes in women and those with MASLD or ascites.

An international consensus has established unified diagnostic criteria for PSVD/NCPF, aiming to improve classification and research in noncirrhotic portal hypertension.

Imaging-detected immune-related adverse events may help predict improved survival in patients with advanced biliary tract cancer receiving durvalumab-based chemotherapy.

The World Health Assembly has formally recognised liver disease within the global NCD agenda, prompting calls for national action and accountability.

Experts at EASL 2026 discussed persistent barriers in hepatitis C testing, including delayed diagnosis, reinfection monitoring, and limited point-of-care access.

Experts at EASL 2026 warned that supplement-induced liver injury is rising alongside the global wellness and herbal supplement boom.

Alcohol policy and liver disease prevention were discussed at EASL 2026, with experts highlighting alcohol’s wider health burden across Europe.